Major breakthrough in quest for cancer vaccine

December 6, 2018, University of Montreal
Credit: CC0 Public Domain

The idea of a cancer vaccine is something researchers have been working on for over 50 years, but until recently they were never able to prove exactly how such a vaccine would work.

Now, a team of researchers at the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal has demonstrated that a vaccine can work. Not only that, it could become an extremely effective, non-invasive and cost-effective -fighting tool.

The team's work was published yesterday in Science Translational Medicine.

The discovery represents a major breakthrough in the quest for a cancer vaccine, a highly competitive pursuit in which numerous research teams around the world are engaged. Unlike other teams, however, IRIC's looked for a solution in an unusual place: non-coding DNA sequences.

Better recognition of antigens

In 2000 and 2005, a number of studies were able to show that immune-defence (T lymphocytes) are capable of recognizing and penetrating cancer cells in order to attack them. "The longer the tumour is infiltrated by the lymphocytes, the longer the patient's survival," explained Claude Perreault, a principal investigator on the IRIC team, along with Pierre Thibault and Sébastien Lemieux. "In patients whose tumours are under greatest attack by T lymphocytes, a drug developed 12 years ago that stimulates their is capable of fighting 25 per cent of cancer cases," Perreault said.

T lymphocytes recognize tumours by the presence of foreign – or peptides – on the surface of cells. However, even if these antigens are recognized by the immune system, they do not sufficiently stimulate it for the lymphocytes to target and destroy them. As such, the search for a vaccine has focused on identifying tumour-specific antigens in order to allow the immune system to attack them more effectively. Since these antigens are the result of defective genes, various research teams have tracked the culprits to the portion of DNA known to encode antigens and proteins. But they have not been successful.

"This portion of DNA makes up only 2 per cent of the human genome," Perreault explained. "DNA sequences known to be "non-coding" may have been "silenced" by the methylation of DNA that affects gene expression. It is here, in this non-coding DNA, which is estimated to account for 98 per cent of the DNA of our cells, that our work is focused."

An effective test vaccine

Using mice injected with various types of cancer cells, the IRIC team was able to identify numerous antigens deriving from the non-coding portion of DNA, several of which were both specific to and common to different types of cancer. This allowed the team to develop a vaccine based on leukemia cells containing some of the identified antigens, which was administered to the mice. The results were highly encouraging.

"Each antigen we tested eliminated 10 to 100 per cent of the leukemia," said Perreault, adding that "some of the antigens protected the mouse for its entire life, despite the reinjection of new leukemia cells. This suggests a long-lasting effect."

Hope for several types of cancer

The same antigens were subsequently identified in leukemia cells in humans. Perreault describes his team's findings as extremely promising and as opening up the possibility for the development of vaccines to treat leukemia and lung cancer in humans.

The IRIC team focused on these two specific types of cancer because they are at opposite ends of the spectrum in terms of the number of mutations at their source. The fact that the vaccine has proven effective to treat leukemia, which is caused by a small number of mutations, holds promise for the efficacy of this therapy in fighting all other types of cancer as well.

"We wouldn't have to reinvent the vaccine for every form of cancer," Perreault noted. At the same time, one of the obstacles in developing a for humans is that our genetic diversity is much greater than that of mice, he added. Nonetheless, he believes that clinical trials with humans could start within the next two to three years.

Developing therapeutic cancer vaccines targeting the antigens identified by the IRIC team would be a cost-effective way to save lives, while at the same time greatly simplifying treatment of this terrible disease, notably by limiting the many side effects of chemotherapy.

An important factor leading to the IRIC discovery is the institute's multidisciplinary approach to research, which combines genomics, bioinformatics and proteomics, Perreault concluded.

Explore further: DNA vaccine targets family of tumor antigens and shows promise for cancer immunotherapy

More information: Céline M. Laumont et al. Noncoding regions are the main source of targetable tumor-specific antigens, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aau5516

Related Stories

DNA vaccine targets family of tumor antigens and shows promise for cancer immunotherapy

September 27, 2018
Scientists at The Wistar Institute have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types ...

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Novel cancer vaccine strategy blocks death of tumor-specific cytotoxic T cells

May 1, 2018
New research published in Cancer Immunology Research by Drs. Esteban Celis and Hussein Sultan of the Georgia Cancer Center at Augusta University could serve as the stepping-stone in constructing vaccines with a greater likelihood ...

Virus-targeting white blood cells in tumors offer intriguing insights into responsiveness to immunotherapy

July 16, 2018
Bystander cells present in human lung and colorectal tumors could indicate how well a patient will respond to immunotherapy, an A*STAR-led study finds.

Researchers use human vaccine to cure prostate cancer in mice

June 19, 2011
University of Leeds researchers, funded by Cancer Research UK, have used a library of DNA to create a vaccine that could be used to treat cancer, according to a study published in Nature Medicine.

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Recommended for you

Two ways cancer resists treatment are actually connected, with one activating the other

December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting ...

Gene variant found in brain complicit in MS onset

December 18, 2018
Multiple sclerosis (MS) is an autoimmune disease affecting the function of the central nervous system. Up to now, most of the 230 genetic variants associated with the disease have been linked to changes in immune cells. However, ...

Gut microbiome regulates the intestinal immune system, researchers find

December 18, 2018
Scientist have long known that bacteria in the intestines, also known as the microbiome, perform a variety of useful functions for their hosts, such as breaking down dietary fiber in the digestive process and making vitamins ...

How a single faulty gene can lead to lupus

December 18, 2018
A research team at the Academy of Immunology and Microbiology, within the Institute for Basic Science (IBS) & Pohang University of Science and Technology (POSTECH) in South Korea has discovered the role of a key gene involved ...

HPV discovery raises hope for new cervical cancer treatments

December 18, 2018
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus.

Vaccine, checkpoint drugs combination shows promise for pancreatic cancers

December 18, 2018
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...


Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (2) Dec 06, 2018
yeah sure
not rated yet Dec 07, 2018
Thats how you were born.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.